| Pharmaceutical Information |
| Drug Name |
Oxyphenbutazone |
| Drug ID |
BADD_D02630 |
| Description |
Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression. |
| Indications and Usage |
Not Available |
| Marketing Status |
approved; withdrawn |
| ATC Code |
M01AA03; M02AA04; S01BC02 |
| DrugBank ID |
DB03585
|
| KEGG ID |
D08324
|
| MeSH ID |
D010113
|
| PubChem ID |
4641
|
| TTD Drug ID |
D06ZPS
|
| NDC Product Code |
Not Available |
| UNII |
H806S4B3NS
|
| Synonyms |
Oxyphenbutazone | Oxyphenylbutazone | Hydroxyphenylbutazone | Diflamil | Tanderil |
|
| Chemical Information |
| Molecular Formula |
C19H20N2O3 |
| CAS Registry Number |
129-20-4 |
| SMILES |
CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)O)C3=CC=CC=C3 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
